A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Rilimogene galvacirepvec; Rilimogene glafolivec
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Sep 2019 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 13 Sep 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 13 Sep 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History